RT-PCR mechanics, immunological tests, and the limits of massive testing
COVID-19 emerged in Wuhan in mid-November 2019 but was not initially recognized as a novel pathogen. The clinical presentation — fever, cough, fatigue — mimicked common respiratory infections. Recognizing a new disease hidden within routine patient flows requires waiting for the signal to become statistically distinguishable — the classic “low signal” problem in epidemiological surveillance.
By January 2nd 2020, the signal was clear enough: a cluster of viral pneumonia cases unresponsive to standard antibiotics, with a clinical presentation closely resembling SARS-CoV (2003). The pathogen was sequenced and shared internationally within days.
Polymerase Chain Reaction, invented by Kary Mullis in 1983, amplifies specific DNA fragments through thermal cycling: denaturation at 95°C (opening the double helix), hybridization at 50-60°C (binding specific primers to the target sequence), and elongation at 72°C (TAQ polymerase synthesizes complementary strands).
For SARS-CoV-2, an RNA virus, a Reverse Transcription step first converts the viral RNA into double-stranded DNA — hence the name RT-PCR. Each cycle doubles the target quantity; 45 cycles produce trillions of copies, turning a weak molecular signal into an unambiguous detection.
The molecular target for RT-PCR must be simultaneously stable (to avoid false negatives from viral mutations) and specific (to avoid false positives from related coronaviruses like those causing common colds).
The NP gene, encoding the nucleoprotein that packages the viral genome, proved ideal: its critical role in virion assembly makes it highly conserved under Darwinian selection pressure. Any mutation disrupting NP function would be lethal to the virus.
RT-PCR (direct detection) confirms active viral presence — essential for early diagnosis when patients may still be asymptomatic or pre-symptomatic. Cost: ~$20 per test, with PCR cyclers ranging from $5,000 to $100,000+.
ELISA (indirect detection) identifies antibodies produced by the immune response: IgM (early infection) and IgG (long-term immunity). These tests are critical for deconfinement decisions — identifying individuals with acquired immunity — but cannot detect active infection before the immune response develops.
Even the most aggressive national testing programs in early 2020 reached only ~1.3% of their populations. Simple arithmetic demonstrates the futility of testing-based containment: with an estimated 133,000 infected individuals in France, testing 10% of the population would still leave over 120,000 undetected carriers — and a single missed case can restart the epidemic.
Strict confinement, combined with barrier gestures and environmental disinfection, remains the primary R₀ reduction strategy during the acceleration phase. Testing should be prioritized for hospital admissions, healthcare professionals, and elderly care facilities.
Rather than impossible massive RT-PCR campaigns, a standardized auto-evaluation questionnaire — deployed via a mobile application feeding an anonymized national database — could provide population-scale triage at minimal marginal cost. Such a digital platform could enable data-driven deconfinement decisions coordinated at the European or global level.